Drug Search Results
More Filters [+]

Bavituximab

Alternative Names: bavituximab
Latest Update: 2024-05-16
Latest Update Note: Clinical Trial Update

Product Description

An IgG3 monoclonal antibody directed against anionic phospholipids with potential antineoplastic activity. Chimeric anti-phosphotidylserine monoclonal antibody binds to anionic phospholipids in a beta 2-glycoprotein I-dependent manner, inhibiting tumor growth by stimulating antibody-dependent cellular cytotoxicity (ADCC) to tumor vessels. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/bavituximab)

Mechanisms of Action: Angiogenesis Inhibitor

Novel Mechanism: No

Modality: Antibody

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Avid Bioservices
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Bavituximab

Countries in Clinic: United States

Active Clinical Trial Count: 2

Highest Development Phases

Phase 2: Glioblastoma|Hepatocellular Carcinoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

STU 102017-015

P2

Active, not recruiting

Hepatocellular Carcinoma

2023-04-21

NCT03139916

P2

Completed

Glioblastoma

2022-08-31

Recent News Events